切换至 "中华医学电子期刊资源库"

中华普通外科学文献(电子版) ›› 2016, Vol. 10 ›› Issue (01) : 31 -35. doi: 10.3877/cma.j.issn.1674-0793.2016.01.004

所属专题: 文献

论著

沉默信息调节因子1与乳腺癌临床病理指标的相关性及生存分析
刘瑞磊1, 陈健宁2, 王佳妮1, 汤谧1, 张艳玲3,()   
  1. 1. 510630 广州,中山大学附属第三医院甲状腺乳腺外科
    2. 510630 广州,中山大学附属第三医院病理科
    3. 510630 广州,中山大学附属第三医院超声科
  • 收稿日期:2015-08-05 出版日期:2016-02-01
  • 通信作者: 张艳玲
  • 基金资助:
    国家自然科学基金青年科学基金项目(81502268); 广东省科技计划社会发展领域科技计划项目(2013B022000017); 广东省医学科研基金资助项目资助项目(B2014149)

Correlation and survival analysis of SIRT1 expression level and clinicopathological features of breast cancer patients

Ruilei Liu1, Jianning Chen2, Jiani Wang1, Mi Tang1, Yanling Zhang3,()   

  1. 1. Depart-ment of Thyroid and Breast Surgery, the Third Affili-ated Hospital of Sun Yat-sen University, Guangzhou 510630, China
    2. Department of Pathology, the Third Affili-ated Hospital of Sun Yat-sen University, Guangzhou 510630, China
    3. Department of Ultrasound, the Third Affili-ated Hospital of Sun Yat-sen University, Guangzhou 510630, China
  • Received:2015-08-05 Published:2016-02-01
  • Corresponding author: Yanling Zhang
  • About author:
    Corresponding author: Zhang Yanling, Email:
引用本文:

刘瑞磊, 陈健宁, 王佳妮, 汤谧, 张艳玲. 沉默信息调节因子1与乳腺癌临床病理指标的相关性及生存分析[J/OL]. 中华普通外科学文献(电子版), 2016, 10(01): 31-35.

Ruilei Liu, Jianning Chen, Jiani Wang, Mi Tang, Yanling Zhang. Correlation and survival analysis of SIRT1 expression level and clinicopathological features of breast cancer patients[J/OL]. Chinese Archives of General Surgery(Electronic Edition), 2016, 10(01): 31-35.

目的

探讨沉默信息调节因子1(SIRT1)在乳腺癌及癌旁组织中的表达及与其他临床病理指标的相关性,并分析其与术后生存数据的关系。

方法

检测120例乳腺癌组织及53例癌旁组织中SIRT1的表达情况,比较两组表达率的差异,以及乳腺癌组SIRT1表达水平与其他临床病理指标的相关性。

结果

乳腺癌组的阳性表达率高于癌旁组织组,差异有统计学意义(53.3% vs 34.0%,χ2=5.533,P=0.02)。临床病理指标分析显示,SIRT1表达水平与肿瘤大小及Ki-67表达情况呈密切相关性(χ2=6.790、21.316,P=0.009、0.000),与年龄、淋巴结转移、临床分期、组织学分级、雌激素受体(ER)、孕雌激素受体(PR)、Her-2表达差异无统计学意义。生存分析显示,SIRT1蛋白表达水平高的乳腺癌患者预后较表达水平低的患者差,差异有统计学意义(χ2=9.320,P<0.05)。

结论

SIRT1在乳腺癌组织中的表达较癌旁组织明显升高,随着肿瘤的增大而表达增强,且与肿瘤增殖指标Ki-67正相关,其高表达的患者预后较差,提示其可能在乳腺癌的发生发展中起着正向促进作用,高表达预示着乳腺癌细胞增殖较快,预后不佳。

Objective

To detect the expression of silent information regulator 1 (SIRT1) in breast cancer and adjacent paracancerous tissues, and to analyze the correlation between its expression level and other clinical features of breast cancer and its significance in prognosis.

Methods

The expression of SIRT1 was detected by immunohistochemistry in 120 breast cancer tissues and 53 adjacent paracancerous tissues. The difference between the two groups and the relationship between SIRT1 expression and other clinical features were tested by chi-square test. Survival analysis was calculated by Kaplan-Meier method, and the survival rate was compared by Log-rank test.

Results

The expression of SIRT1 in breast cancer group was significantly higher than adjacent paracancerous tissues group (53.3% vs 34.0%, χ2=5.533, P=0.02). SIRT1 expression level showed positive correlation with tumor size and expresion of Ki-67 (χ2=6.790, 21.316, P=0.009, 0.000), but no statistical correlation with lymph node metastasis, clinical stage, histological grade, ER, PR and Her-2 expression. Statistical analysis showed that compared with low SIRT1 expression, patients with high SIRT1 expression level had significantly poorer prognosis (χ2=9.320, P<0.05).

Conclusions

The expression of SIRT1 is obviously increased in breast cancer patients than that in adjacent paracancerous tissues, and its expression is correlated with tumor size and expression of Ki-67. These results may implicate that SIRT1 will improve the development of breast cancer and the high-er expression of SIRT1 indicates the activated proliferation and poor survival rate.

表1 乳腺癌患者SIRT1表达水平与临床病理指标的关系[例(%)]
图1 SIRT1蛋白的免疫组化染色(HE, ×400)
图2 Kaplan-Meier生存曲线分析120例乳腺癌患者SIRT1表达水平与预后的关系
2
Liu T,Liu PY,Marshall GM. The critical role of the class Ⅲ his-tone deacetylase SIRT1 in cancer[J]. Cancer Res, 2009, 69(5): 1702-1705.
3
Song NY,Surh YJ. Janus-faced role of SIRT1 in tumorigenesis[J]. Ann N Y Acad Sci, 2012, 1271: 10-19.
4
Deng CX. SIRT1, is it a tumor promoter or tumor suppressor?[J]. Int J Biol Sci, 2009, 5(2): 147-152.
5
张嘉庆,王殊,谢菲.不断提高我国乳腺癌综合治疗水平[J/CD].中华普外科手术学杂志:电子版, 2011, 5(4): 367-372.
6
Guarente L. Sir2 links chromatin silencing, metabolism, and aging[J]. Genes Dev, 2000, 14(9): 1021-1026.
7
Vaziri H,Dessain SK,Ng EE, et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase[J]. Cell, 2001, 107(2): 149-159.
8
Kim EJ,Kho JH,Kang MR, et al. Active regulator of SIRT1 coop-erates with SIRT1 and facilitates suppression of p53 activity[J]. Mol Cell, 2007, 28(2): 277-290.
9
Sung JY,Kim R,Kim JE, et al. Balance between SIRT1 and DBC1 expression is lost in breast cancer[J]. Cancer Sci, 2010, 101(7): 1738-1744.
10
Zschoernig B,Mahlknecht U. SIRTUIN 1: regulating the regulator[J]. Biochem Biophys Res Commun, 2008, 376(2): 251-255.
11
Motta MC,Divecha N,Lemieux M, et al. Mammalian SIRT1 re-presses forkhead transcription factors[J]. Cell, 2004, 116(4): 551-563.
12
Dai JM,Wang ZY,Sun DC, et al. SIRT1 interacts with p73 and suppresses p73-dependent transcriptional activity[J]. J Cell Physi-ol, 2007, 210(1): 161-166.
13
Wong S,Weber JD. Deacetylation of the retinoblastoma tumour suppressor protein by SIRT1[J]. Biochem J, 2007, 407(3): 451-460.
14
Li K,Casta A,Wang R, et al. Regulation of WRN protein cellular localization and enzymatic activities by SIRT1-mediat-ed deacetylation[J]. J Biol Chem, 2008, 283(12): 7590-7598.
15
Doyle SL,Donohoe CL,Lysaght J, et al.Visceral obesity, metabol-ic syndrome, insulin resistance and cancer[J]. Proc Nutr Soc, 2012, 71(1): 181-189.
16
Eades G,Yao Y,Yang M, et al. miR-200a regulates SIRT1 ex-pression and epithelial to mesenchymal transition (EMT)-like transformation in mammary epithelial cells[J]. J Biol Chem, 2011, 286(29): 25992-26002.
1
Jemal A,Bray F,Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90.
17
Nalls D,Tang SN,Rodova M, et al. Targeting epigenetic regula-tion of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells[J]. PLoS One, 2011, 6(8): e24099.
18
Huffman DM,Grizzle WE,Bamman MM, et al. SIRT1 is signifi-cantly elevated in mouse and human prostate cancer[J]. Cancer Res, 2007, 67(14): 6612-6618.
[1] 李洋, 蔡金玉, 党晓智, 常婉英, 巨艳, 高毅, 宋宏萍. 基于深度学习的乳腺超声应变弹性图像生成模型的应用研究[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 563-570.
[2] 河北省抗癌协会乳腺癌专业委员会护理协作组. 乳腺癌中心静脉通路护理管理专家共识[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 321-329.
[3] 刘晨鹭, 刘洁, 张帆, 严彩英, 陈倩, 陈双庆. 增强MRI 影像组学特征生境分析在预测乳腺癌HER-2 表达状态中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 339-345.
[4] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[5] 邱琳, 刘锦辉, 组木热提·吐尔洪, 马悦心, 冷晓玲. 超声影像组学对致密型乳腺背景中非肿块型乳腺癌的诊断价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 353-360.
[6] 程燕妮, 樊菁, 肖瑶, 舒瑞, 明昊, 党晓智, 宋宏萍. 乳腺组织定位标记夹的应用与进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 361-365.
[7] 涂盛楠, 胡芬, 张娟, 蔡海峰, 杨俊泉. 天然植物提取物在乳腺癌治疗中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 366-370.
[8] 朱文婷, 顾鹏, 孙星. 非酒精性脂肪性肝病对乳腺癌发生发展及治疗的影响[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 371-375.
[9] 周荷妹, 金杰, 叶建东, 夏之一, 王进进, 丁宁. 罕见成人肋骨郎格汉斯细胞组织细胞增生症被误诊为乳腺癌术后骨转移一例[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 380-383.
[10] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[11] 韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[12] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[13] 王玲艳, 高春晖, 冯雪园, 崔鑫淼, 刘欢, 赵文明, 张金库. 循环肿瘤细胞在乳腺癌新辅助及术后辅助治疗中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 630-633.
[14] 赵林娟, 吕婕, 王文胜, 马德茂, 侯涛. 超声引导下染色剂标记切缘的梭柱型和圆柱型保乳区段切除术的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 634-637.
[15] 司钦亮, 毕世龙, 焦慧骁, 李世照, 陈哲禹, 武玉东. 精索去分化脂肪肉瘤两例并文献复习[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 585-590.
阅读次数
全文


摘要